Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway

DSpace/Manakin Repository

Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway

Citable link to this page

 

 
Title: Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway
Author: Cai, Jun; Yi, Fang-Fang; Bian, Zhou-Yan; Shen, Di-Fei; Yang, Long; Yan, Ling; Tang, Qi-Zhu; Yang, Xin-Chun; Li, Hongliang

Note: Order does not necessarily reflect citation order of authors.

Citation: Cai, Jun, Fang-Fang Yi, Zhou-Yan Bian, Di-Fei Shen, Long Yang, Ling Yan, Qi-Zhu Tang, Xin-Chun Yang, and Hongliang Li. 2009. “Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway.” Journal of Cellular and Molecular Medicine 13 (5): 909-925. doi:10.1111/j.1582-4934.2008.00620.x. http://dx.doi.org/10.1111/j.1582-4934.2008.00620.x.
Full Text & Related Files:
Abstract: Abstract Oxidative stress plays a critical role in the progression of pathological cardiac hypertrophy and heart failure. Because crocetin represses oxidative stress in vitro and in vivo, we have suggested that crocetin would repress cardiac hypertrophy by targeting oxidative stress-dependent signalling. We tested this hypothesis using primary cultured cardiac myocytes and fibroblasts and one well-established animal model of cardiac hypertrophy. The results showed that crocetin (1–10 μM) dose-dependently blocked cardiac hypertrophy induced by angiogensin II (Ang II; 1 μM) in vitro. Our data further revealed that crocetin (50 mg/kg/day) both prevented and reversed cardiac hypertrophy induced by aortic banding (AB), as assessed by heart weight/body weight and lung weight/body weight ratios, echocardio-graphic parameters and gene expression of hypertrophic markers. The inhibitory effect of crocetin on cardiac hypertrophy is mediated by blocking the reactive oxygen species (ROS)-dependent mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase-1/2 (MEK/ERK1/2) pathway and GATA binding protein 4 (GATA-4) activation. Further investigation demonstrated that crocetin inhibited inflammation by blocking nuclear factor kappa B (NF-κB) signalling and attenuated fibrosis and collagen synthesis by abrogating MEK-ERK1/2 signalling. Overall, our results indicate that crocetin, which is a potentially safe and inexpensive therapy for clinical use, has protective potential in targeting cardiac hypertrophy and fibrosis by suppression of ROS-dependent signalling pathways.
Published Version: doi:10.1111/j.1582-4934.2008.00620.x
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823407/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:15034965
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters